BriovaRx, LLC v. Transcript Pharmacy, Inc.

163 So. 3d 311, 2015 Miss. App. LEXIS 245, 2015 WL 2024660
CourtCourt of Appeals of Mississippi
DecidedMay 5, 2015
Docket2013-CA-01158-COA
StatusPublished
Cited by3 cases

This text of 163 So. 3d 311 (BriovaRx, LLC v. Transcript Pharmacy, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals of Mississippi primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
BriovaRx, LLC v. Transcript Pharmacy, Inc., 163 So. 3d 311, 2015 Miss. App. LEXIS 245, 2015 WL 2024660 (Mich. Ct. App. 2015).

Opinion

*313 MAXWELL, J.,

for the Court:

¶ 1. The circuit court denied Brio-vaRX’s motion to compel arbitration because BriovaRX was not a party to the arbitration agreement it sought to enforce. But in Mississippi, a non-signatory can enforce an arbitration agreement when the non-signatory maintained a close legal relationship with the signatory to the agreement and the plaintiff has alleged “substantially interdependent and concerted misconduct” between the non-signatory and signatory. 1 Here, both conditions were met. BriovaRX is a subsidiary of Catamaran Corporation, which had entered into an agreement with Transcript Pharmacy, Inc. This agreement included a broad arbitration clause. When you couple this with the fact Transcript had alleged BriovaRX’s “joint conduct” with Catamaran was the source of its injury, the exception allowing non-signatories to compel arbitration applied.

¶ 2. Because we find BriovaRX, though a non-signatory, had a right under these circumstances to enforce the arbitration agreement between Transcript and Catamaran, and because we also find neither BriovaRX nor Catamaran waived the right to arbitrate the new claims raised in Transcript’s 2012 amended complaint, it was error for the circuit court to deny Brio-vaRX’s and Catamaran’s motions to compel arbitration. We reverse and remand for the circuit court to grant the motions to compel arbitration.

Background Facts and Procedural History

I. Initial Lawsuit

¶ 3. Interestingly, BriovaRX and Transcript started off on the same side. In 2009, Transcript sued Catalyst RX, the pharmacy-benefits manager for the Mississippi State and School Employees’ Life and Health Plan (State Plan), for dropping Transcript from the State Plan. 2 Transcript claimed that Mississippi’s “any willing provider” statute for pharmacies, Mississippi Code Annotated section 83-9-6 (Rev.2011), entitled it to participate in the State Plan. Transcript prayed for emergency and permanent injunctive relief. See Miss.Code Ann. § 83-9-6(6) (creating a civil action for injunctive relief for violation of this section). It also sought a declaratory judgment that section 83-9-6 applied to the State Plan. Additionally, it requested money damages under several tort theories.

¶ 4. BriovaRX- — -a specialty pharmacy then named Medfusion RX — intervened as a similarly situated plaintiff.

¶ 5. Medfusion RX had entered a similar agreement with Catalyst RX as Transcript had. Both of these agreements contained broad arbitration clauses. Relying on these clauses, Catalyst RX moved to compel arbitration. But later Catalyst RX agreed that the declaratory action — which sought to resolve the legal question whether section 83-9-6 applied to the State Plan — -should be decided by the circuit court. So Catalyst RX agreed to withdraw its motion to compel arbitration. In exchange, Transcript and Medfusion RX agreed to dismiss their claims for money damages. The dismissal of these claims was without prejudice. But Transcript and Medfusion RX expressly assured Catalyst RX that any later pursuit of their damages claims would happen in the arbitration forum.

*314 ¶6. The declaratory action was resolved in Transcript and Medfusion RX’s favor. In February 2011, through a grant of partial summary judgment, the circuit court declared the any-willing-provider statute applied to the State Plan. While it took a year, Catalyst RX had this judgment certified as final and filed a notice of appeal. But that appeal was later withdrawn, owing to the fact that, in a separate appeal, the Mississippi Supreme Court conclusively held the any-willing-provider statute entitled willing pharmacies like Transcript to act as providers to. State Plan members. Miss. State & Sch. Emps’ Life & Health Plan v. KCC, Inc., 108 So.3d 932 (Miss.2013).

II. Corporate Realignments

¶ 7. While that first appeal was pending, several significant events happened.

¶ 8. First, both Catalyst RX and Med-fusion RX changed their names and their legal relationship to each other. After a series of mergers, Catalyst RX became Catamaran. As part of these corporate changes, Catamaran acquired Medfusion RX. Catamaran then rebranded Medfusion RX as BriovaRX. Thus, Catamaran’s once legal foe on the other side of the “v.” became part of its corporate family, designated as Catamaran’s specialty pharmacy.

¶ 9. Second, in light of this change, Catamaran — on Catalyst RX letterhead— mailed its customers nationwide a letter informing them their specialty pharmacy was changing and directing them to call for further instructions. Catamaran acknowledges this letter was erroneously sent to members of the State Plan. Because of the supreme court’s ruling on the any-willing-provider question, Transcript legally could continue to be the specialty pharmacy for State Plan members.

III. Amended Complaint

¶ 10. What Catamaran characterized as a mistake — sending the letter to State Plan members — Transcript called a conspiracy. As soon as it learned of the September 2012 letter, Transcript immediately moved to amend its complaint. The proposed amended complaint focused on the letter, alleging Catamaran and Transcript’s former ally, BriovaRX f/k/a Med-fusion RX, conspired together to steal Transcript’s customers and that their “joint actions” had harmed Transcript. Transcript sought money damages under various tort theories — but only against BriovaRX. Transcript was careful in its prayer for relief to state that it was not seeking tort damages from Catamaran, but instead just injunctive and declaratory relief.

¶ 11. In light of these new allegations, Catamaran renewed its motion to compel arbitration. And while BriovaRX did not assert the right to arbitrate in its initial answer to Transcript’s amended complaint, it soon after filed a motion to amend its answer to include an arbitration defense. It also filed a separate motion to compel arbitration.

¶ 12. Both Catamaran’s and BriovaRX’s motions to compel arbitration were heard together, along with BriovaRX’s motion to amend its answer. The circuit court denied all three motions. The court found Catamaran had waived its right to compel arbitration by participating thus far in the now three-year-old litigation. And the court found BriovaRX, as a third-party to the Catamaran/Transcript agreement, had no right to enforce the arbitration clause found in that agreement. And because BriovaRX had no right to compel arbitration, there was no reason to allow Brio-vaRX to amend its answer with a futile assertion of arbitration.

*315 ¶ 13. Because the denial of a motion to compel arbitration is a final judgment conferring appellate jurisdiction, Catamaran and BriovaRX immediately appealed. See, e.g., Wolgin v. Experian Info. Solutions, Inc., 101 So.3d 1160, 1165-66 (¶ 16) (Miss.2012) (recognizing appellate jurisdiction of the denial of a motion to compel arbitration).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
163 So. 3d 311, 2015 Miss. App. LEXIS 245, 2015 WL 2024660, Counsel Stack Legal Research, https://law.counselstack.com/opinion/briovarx-llc-v-transcript-pharmacy-inc-missctapp-2015.